Johnson & Johnson's long-awaited chemotherapy Yondelis (trabedectin) is finally approved for sarcoma in the US, having been approved in multiple other markets already, but leading a wave of potential new entrants in an area of high unmet need.
FDA approved Yondelis on Oct
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?